Tags : Biogen

Biogen Signs an Agreement with Denali on LRRK2 Program for

Shots: Denali to receive $560M up front, $465M as equity investment at a price of $34.94/ share, representing 11.2% of Denali’s Pro-forma outstanding stock along with $1.125B as milestones. The two companies will codevelop Denali’s LRRK2 inhibitor for PD and co-commercialize it in the US and China while Biogen has the right to commercialize the […]Read More

Weekly Snapshot (Jul 06 – 10, 2020)

1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, FDA, Acceptance, BLA, Tralokinumab, Treat, Adults, Moderate to Severe, Atopic Dermatitis 2. Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring Published Date:  Jul 10, […]Read More

Biogen and Eisai Complete the Submission of BLA to the

Shots: The completed submission followed ongoing collaboration with the FDA and includes clinical data from the P-III EMERGE and ENGAGE studies along with the P-Ib PRIME study. Additionally, Biogen has requested Priority Review The P-III EMERGE study met its 1EPs in patients treated with a high dose showed a reduction of clinical decline from baseline […]Read More

Biogen Signs a License Agreement with Massachusetts Eye and Ear

Shots: Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all US FDA required IND enabling studies, clinical development, and commercialization The companies collaborated to develop a therapy for IRDs due to mutations in the PRPF31 gene. Research performed at Harvard Ophthalmology demonstrated that AAV-mediated gene augmentation therapy […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is, in turn, enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position. The top 20 companies’ chartbusters changed their 2019 ranking, but the history of Johnson and Johnson did not change and it continued being at the […]Read More

Insights+ COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests.  This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. During the last four months […]Read More

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

PharmaShots Weekly Snapshot (March 16-20, 2020)

1. Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform Published: Mar 19, 2020 | Tags: Merck, Collaborates, Dragonfly, Develop, Commercialize, Novel Therapies, Utilizing, TriNKET Platform 2.  BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US Published: Mar 20, 2020 | Tags: BGI, Reports, Availability, RT-PCR, SARS-CoV-2 […]Read More